ChitogenX (CHGX) AI Stock Analysis

• Market Cap: $415.65K
• Dividend Yield: N/A
• Average Volume (3M): 29.34K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: N/A
• EPS Growth: 66.31%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 83,129,520
• 10 Day Avg. Volume: 67,098
• 30 Day Avg. Volume: 29,342
• PEG Ratio: -0.02
• Price to Book (P/B): -0.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 24 Underperform
• Price Target: ―

ChitogenX's overall stock score reflects significant financial instability with no revenue, high debt levels, and negative cash flows, coupled with technical indicators pointing towards bearish trends. The lack of earnings or dividends makes the stock less appealing from a valuation perspective.

ChitogenX Business Overview & Revenue Model

Company Description

ChitogenX (CHGX) is a biotechnology company specializing in regenerative medicine and advanced medical technologies. The company focuses on developing innovative solutions for tissue repair and healing, primarily leveraging its proprietary chitosan-based platform. ChitogenX is committed to improving patient outcomes through its cutting-edge products designed for a variety of medical applications, including orthopedics and wound care.

How the Company Makes Money

ChitogenX makes money through the development, licensing, and sales of its proprietary medical products and technologies. The company's primary revenue streams include direct sales of its chitosan-based products to healthcare providers and institutions, as well as licensing agreements with other medical device and pharmaceutical companies that incorporate ChitogenX's technology into their own product offerings. Additionally, ChitogenX may engage in strategic partnerships and collaborations to expand its market reach and enhance its product pipeline, further contributing to its earnings.

ChitogenX Financial Statement Overview

Summary

ChitogenX faces significant financial challenges with no revenue generation, high levels of debt, and negative cash flows. The company shows a pattern of financial instability, with profitability and liquidity concerns that need to be addressed to ensure sustainable operations.

Income Statement

ChitogenX has reported negative gross profit and net income with no revenue, indicating that the company is not currently generating sales but incurring costs. The lack of revenue growth and negative margins highlight significant profitability challenges.

Balance Sheet

The balance sheet shows negative stockholders' equity and a high debt-to-equity ratio, both of which suggest financial instability and potential risks in leveraging. The equity ratio is negative due to negative equity, indicating that the company is financed more by debt than equity.

Cash Flow

ChitogenX's cash flow statements reveal ongoing negative operating and free cash flows, indicating that the company is consuming more cash than it generates. The cash flow from operations is insufficient to cover net income, suggesting potential liquidity challenges.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-27.00K	-42.00K	-59.00K	-69.00K	-89.00K	-119.00K
	EBIT
-954.00K	-2.83M	-4.81M	-3.37M	-2.93M	-2.18M
	EBITDA
-758.00K	-2.69M	-4.65M	-3.19M	-2.54M	-2.22M
	Net Income Common Stockholders
-1.55M	-1.55M	-6.34M	-6.05M	-4.61M	-2.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
48.00K	35.00K	108.00K	313.00K	2.38M	302.00K
	Total Assets
385.00K	534.00K	738.00K	1.12M	3.28M	1.29M
	Total Debt
4.23M	3.88M	5.56M	5.71M	4.62M	2.67M
	Net Debt
4.19M	3.84M	5.46M	5.40M	2.24M	2.36M
	Total Liabilities
7.75M	6.71M	10.58M	8.23M	5.08M	3.69M
	Stockholders Equity
-7.36M	-6.18M	-9.84M	-7.10M	-1.80M	-2.40M
Cash Flow		Free Cash Flow
-153.00K	-1.01M	-3.20M	-3.25M	-2.98M	-1.59M
	Operating Cash Flow
-153.00K	-1.01M	-3.20M	-3.22M	-2.98M	-1.59M
	Investing Cash Flow
0.00	0.00	204.79K	-33.00K	-3.00K	0.00
	Financing Cash Flow
75.00K	937.00K	2.94M	1.16M	5.05M	1.37M

ChitogenX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CHGX, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CHGX.

ChitogenX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZOMD	81 Outperform	$82.31M	6.86	67.52%	―	104.46%	―
CRON	72 Outperform	$1.13B	16.01	4.61%	―	38.16%	―
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
NGEN	48 Neutral	$431.44M	―	-248.14%	―	―	7.77%
BCT	43 Neutral	C$28.29M	―	-478.64%	―	―	56.78%
ONC	43 Neutral	$51.85M	―	-211.24%	―	―	0.10%
CHGX	24 Underperform	$415.65K	―	21.10%	―	―	66.31%

ChitogenX Corporate Events

ChitogenX Shows Financial Improvement in Q3 2025

ChitogenX Inc. reported a reduced net loss of $0.6 million for the third quarter of 2025, marking a 23% improvement from the previous year. The company also achieved a significant 71% reduction in EBITDA loss year-to-date, reflecting their efforts to minimize operating expenses and focus on securing funding through partnerships.